​Kevin Chiang

​Kevin Chiang is one of the founders and CEO of TF Capital. Kevin has over 20 years of hands-on experience in investment management and managed numerous successful Chinese IPOs in the U.S. and China. Kevin's focus has been on active leadership role on the formation, development and business strategy of our portfolio companies, as well as actively identiyfing and evaluating new investments. Prior to TF Capital, Kevin served at Morningside Capital and Guanshi Captial.

​Kevin holds a Master of Science from Columbia University and a Master of Business Administration from The Wharton Business School of the University of Pennsylvania.


​Ming Li

​Ming Li is the Vice President of TF Capital. Ming joined TF Capital at its founding and has extensive experience in drug development, pharmaceutical market analysis, consulting and investment. Ming's focus is working with exceptional entrepreneurs to create companies around novel insights in biology and new approaches to drug discovery. Prior to TF Capital, Ming served at the Process Chemistry Department in Novartis, China GlaxoSmithKline R&D Center and IMS Consulting Group. 

​Ming holds a Doctor of Philosophy from Shanghai Institute of Organic Chemistry and a Postdoctoral from the University of Toulouse III and University of Paris VI.


​Song Zhou

​Song Zhou is an Investment Officer at TF Capital. Song is familiar with China's pharmaceutical market and experienced in clinical research. Song focuses on new advances in biology and drug discovery technologies as well as novel therapeutics. Prior to TF Capital, Song served at the Department of Neurosurgery at Shanghai's First People's Hospital, IMS Consulting Group and Medical Affairs Department at GlaxoSmithKline.

​Song holds a Doctor of Medicine from Shanghai Jiao Tong University.


​Tingting Zhang

​Tingting Zhang is the Legal Counselor at TF Capital. Tingting is experienced in Sino-US trade law and domestic and foreign company investment agreement regulations. Tingting focuses on compliance and legislation. Prior to TF Capital, Tingting served at the Compliance Department at Life Tech and Johnson&Johnson.

​Tingting holds a Bachelor of Law from Fudan University and Masters of Law from University of Southern California. Tingting is admitted to practice law in the State of New York.



​Xiaoping Ye

​Xiaoping Ye is the Founder and CEO of Hangzhou Tigermed Consulting CO., Ltd. Previously, Xiaoping was the Medical Director of Roche China. Xiaoping held senior positions earlier in his career at Janssen and Bristol-Myers Squibb. Xiaoping has decades of drug development experience and extensive network in the healthcare industry. 

Xiaoping holds a Doctor of Philosophy in Immunology from Oxford University and Executive Master of Business Administration from Peking University.

​​Wen Chen

​Wen Chen is the Vice President and Head of Business Development of Hangzhou Tigermed Consulting CO., Ltd. Previously, Wen was the Chief Operating Officer of HD Biosciences CO., Ltd and Executive Vice President of Huya Bioscience International. Wen served at Amgen earlier in his career. Wen has decades of experience in biomedicine R&D and business development.

Wen holds a Master of Science in Oncology from Washington University and Master of Business Administration from Durham University.

​Gene Hsu

​Gene Hsu is a specialist in the field of toxicology and drug development. Previously, Gene was the Vice President of Taigen Biotechnology Co., Ltd. Gene held positions earlier in his career at Merck and and the National Shanghai Center of New Drug Safety Evaluation and Research (NDSER). Gene is a National 1,000 Talent Plan Expert.

​Gene holds a Doctor of Philosophy from Massachusetts Institute of Technology and Postdoctoral from University of California, Berkeley.

​Xiaoyang Fu

​Xiaoyang Fu is the Founder and Managing Director of Jyton Group, a leading medical device and pharmaceutical consulting firm in China. Previously, Xiaoyang was the former China General Manager of British Standards Institution. Xiaoyang has over 15 years of experience in medical device regulations and information services.

​Xiaoyang holds a Master of Science from Shenyang Pharmaceutical University